• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>IMS Health

IMS Health

RX Safes Inc RXSF

Last Price$0.06Day Change (%)10.00%
Open Price$0.05Day Change ($)0.00
Day Range0.04–0.0652-Week Range0.03–1.00

As of Thu 3/26/2015 2:48:00 PM | USD

  1. All
  2. Morningstar Articles
  3. 3rd Party
  1. IMS Health Announces Pricing of Senior Notes to Finance Proposed Acquisition of Cegedim’s CRM and Strategic Data Businesses

    IMS Health Announces Pricing of Senior Notes to Finance Proposed Acquisition of Cegedim’s CRM and Strategic Data Businesses

  2. Mylan Launches First and Only Available Intermediate Dosage Strengths of Fentanyl Transdermal System 37.5, 62.5 and 87.5 mcg/hr

    Mylan Launches First and Only Available Intermediate Dosage Strengths of Fentanyl Transdermal System 37.5, 62.5 and 87.5 mcg/hr

  3. Synthetic Biologics' SYN-004 Data for Protection of Microbiome Selected for Late-Breaking Poster Presentation at Digestive Disease Week® 2015

    Synthetic Biologics' SYN-004 Data for Protection of Microbiome Selected for Late-Breaking Poster Presentation at Digestive Disease Week® 2015

  4. Mylan Launches Generic Subutex® Sublingual Tablets

    Mylan Launches Generic Subutex® Sublingual Tablets

  5. FDA approves first biosimilar drug

    FDA approves first biosimilar drug

  6. FDA Warns on Low-Testosterone Drugs -- Update

    FDA Warns on Low-Testosterone Drugs -- Update

  7. Our Take on the Second Quarter

    Despite the Fed taper, a U.S. economy struggling to shake off the winter blues, and a slowing China, stocks continued their remarkable winning streak from April through June.

  8. Trouble in Plain Sight

    IMS Health is on the right track for growth.

  9. Our Take on the Fourth Quarter

    A look back at the winners and losers of the final quarter of a tumultuous year.

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.